Key result
Visit-to-visit systolic blood pressure variability is a significant predictor of stroke, cardiovascular, and all-cause mortality, independently of mean blood pressure and age.
Answers are grounded in this paper and cite their sources.
Visit-to-visit blood pressure variability is a promising prognostic marker for cardiovascular risk, but requires standardized assessment methods before routine clinical application.
Essential hypertension is considered a major public health problem that is estimated to account for more than 7.5 million deaths annually.1 Vascular and overall mortality has been long linked with blood pressure (BP) levels.2 Beyond BP levels, the novel notion of visit-to-visit-systolic BP variability (VVV) has emerged as a significant predictor of cardiovascular and overall mortality, as confirmed in the meta-analysis by Tai and colleagues3 published in this issue of The Journal of Clinical Hypertension. Initial reports on the effects of VVV on cardiovascular outcomes date back to 1997, when the Honolulu Heart Program showed an association between VVV and incidence of coronary heart disease.4 In a landmark study of this field, Rothwell and colleagues5 documented VVV as a strong predictor of stroke, independently of mean systolic BP, analyzing data from the United Kingdom Transient Ischemic Attack (UK-TIA) study, three validation cohorts, and the Anglo-Scandinavian Cardiac Outcomes Trial––Blood Pressure–Lowering Arm (ASCOT-BPLA). Since then, a number of studies have further investigated the pathophysiological and clinical role of VVV. In smaller studies, VVV has been significantly correlated with subclinical markers of vascular dysfunction, including arterial stiffness, endothelial dysfunction, and atherosclerosis, and has proven to be an independent predictor of major cardiovascular events.6, 7 The prognostic significance of VVV receives further merit by the systematic review and meta-analysis by Tai and colleagues. The authors thoroughly review prospective studies on VVV and outcomes of cardiovascular, cerebrovascular, and total mortality. Of note, this meta-analysis included a total sample size of 77,299 individuals with a mean follow-up of 6.3 years from 13 clinical trials in the general population and in patients with comorbidities, such as essential hypertension, diabetes mellitus, or end-stage renal disease. Independently of mean BP and age, VVV has proven to be a significant predictor of stroke, cardiovascular, and all-cause mortality. In line with the results of Tai and colleagues are the findings from a most recent meta-analysis on the subject by Diaz and coworkers.8 As pointed out by both manuscripts, the lack of standardization of VVV assessment represents a major methodological flaw that inhibits further application of the method. In particular, a number of methods have been proposed for VVV assessment, including standard deviation, coefficient of variation, variability independent of the mean, and average real variability. Tai and colleagues investigated the prognostic significance of all indices and concluded that standard deviation better predicted hard endpoints in their dataset. Beyond the method used to calculate VVV, the number of visits, the number of BP measurements per visit, and the time interval between visits represent additional elements of heterogeneity among studies in this field that need to be further evaluated. Special attention should also be paid to differences among special populations and study follow-up. Differences in VVV may exist not only in different disease entities but also in different stages of essential hypertension. As pointed out by the European Lacidipine Study on Atherosclerosis (ELSA) trial, data about the additive value of VVV vs mean BP levels on treated patients with mild to moderate essential hypertension are not convincing.9 On the other hand, a more recent double-blind placebo-controlled study published in this Journal10 reported a strong association between VVV and cardiovascular mortality in elderly patients with isolated systolic hypertension after 17 years of follow-up. Above the role of VVV as another prognostic marker of cardiovascular and all-cause mortality, the potential benefits of lowering VVV would be of great interest. Studies of the effects of antihypertensive treatment on VVV have been limited so far. Favorable effects of calcium channel blockers have been confirmed in a meta-analysis by Webb and Rothwell.11 They show that a higher dose of a calcium channel blocker alone or combination with other agents reduces VVV, in contrast to the effects of β-blockers that either increase or do not affect VVV, respectively. In a recent post hoc analysis of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) published in this Journal,12 chlorthalidone and amlodipine have been associated with lower VVV in systolic BP than lisinopril. However, results from the ELSA study have shown only a slight reduction in VVV of systolic BP in mild to moderate hypertensive patients treated with lacidipine compared with patients treated with atenolol.13 Another important step in the effort to reduce VVV is better understanding of factors associated with BP variability. Except for factors that cannot be modified, such as age, sex, race, and history,5, 14 data from the third report of the National Health and Nutrition Examination Survey (NHANES III) have also shown an association of mean BP and pulse pressure levels with VVV in the general population.14 In addition, adherence to antihypertensive treatment has also been proposed as a factor affecting VVV.15 Although low adherence was associated with VVV, it was not found to be a major predictor of VVV in multivariate models of a meticulous analysis of adherence to antihypertensive treatment.16 Lastly, VVV has still to prove its prognostic ability against out-of-office BP variability assessed either through ambulatory BP monitoring (ABPM) or home BP measurements. Although seemingly similar, these two forms of BP variability may differ in pathophysiology and clinical interpretation as VVV refers to BP differences between measurements in a control setting without physical activity. In favor of this argument, a number of studies have reported a weak association between VVV and variability in ABPM.5, 9 However, pathophysiology and clinical interpretation of both entities remain under investigation. Furthermore, as pointed out by Boggia and colleagues,17 out-of-office BP variability provided by standardized measurements may contribute significantly to cardiovascular stratification, but not over and beyond BP levels. In accordance with this, whether VVV has to add significant information and therefore improve cardiovascular risk stratification in patients with hypertension needs further investigation. In other words, has VVV an incremental value over and above the other markers already associated with cardiovascular morbidity and mortality and used in risk stratification? If yes, the investigation of parameters associated with its pathophysiology are of great importance and need to be further clarified. VVV represents a promising novel research and clinical tool in patients with essential hypertension. Further well-designed studies will lead the future in order to translate findings from this promising research area into clinical practice and evaluate the role of VVV as a marker of cardiovascular risk stratification and as a novel target in the management of patients with essential hypertension. None declared.
No takes yet. Share an insight, caveat, or question.
Gavriilaki et al. (2015) conducted an editorial in Essential hypertension (n=77,299). Visit-to-visit systolic blood pressure variability (VVV) was evaluated on Stroke, cardiovascular, and all-cause mortality. Visit-to-visit systolic blood pressure variability is a significant predictor of stroke, cardiovascular, and all-cause mortality, independently of mean blood pressure and age.
Synapse has enriched 10 related papers. Consider them for comparative context: